(PDF) P2.01-128 Low Positivity Rate in T790M Detection With

P2.01-128 Low Positivity Rate in T790M Detection With ctDNA in NSCLC and Post EGFR-TKI Progression – Timing or Sensitivity?

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1183

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P2.01-32 Economic Evaluation of Diagnostic Platforms for T790M Detection in Post EGFR-TKI NSCLC in Brazil

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.13-14 the Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.04-09 Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC With Progression on Prior EGFR-TKI

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-06 Concomitant Plasma-Genotyped T790M Positivity and Small Cell Carcinoma Transformation in EGFR-Mutated NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Journal of Thoracic Oncology

Respiratory Medicine

English

MA15.10 Loss of T790M Mutation Is Associated With Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M

Journal of Thoracic Oncology

Respiratory Medicine

English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management

English

First-Line Treatment in NSCLC Harboring EGFR Common Mutations: EGFR TKI in Monotherapy or in Combination With Anti-Vegf?

Expert Review of Anticancer Therapy

English

Combined Therapy With EGFR TKI and Gambogic Acid for Overcoming Resistance in EGFR‑T790M Mutant Lung Cancer

Oncology Letters

Cancer Research

English